East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more East Resources Acquisition Charts. Click Here for more East Resources Acquisition Charts.](/p.php?pid=staticchart&s=N%5EERES&p=8&t=15)
Two International Biopharmaceutical Organizations Sign Agreements with
eResearchTechnology Totaling More Than $1.7 Million for Thorough Phase 1 ECG
Studies
eResearchTechnology to Provide Cardiac Safety Monitoring and Information
Distribution Services
PHILADELPHIA, Feb. 20 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), , a leading provider of centralized electrocardiographic (ECG) collection
and interpretation services, announced today that it has received agreements for
more than $1.7 million in cardiac safety monitoring and services from two
international biopharmaceutical organizations for two drug candidates in
clinical development.
The agreements cover an extensive Phase I study for each compound. eRT is
providing comprehensivesupport including the provision, training and ongoing
assistance required for effective use of digital 12-lead Holter equipment
designed to facilitate 24-hour digital recording of cardiac safety data that is
subsequently provided to eRT for analysis. eRT will perform digital collection,
measurement, interpretation, review, and distribution of cardiac safety data
through its EXPeRT workflow enabled data handling technology, the first solution
in production that was designed explicitly to meet emerging international
regulatory guidance and technical standards. Each study is targeted for
completion over a 90-day period.
"We are pleased to have been awarded these important studies, which illustrate
the continued adoption of emerging FDA guidelines and international standards
that designate the Thorough Phase I ECG Study as the definitive approach to
determining the cardiac effects of new therapies on healthy volunteers," said
Scott Grisanti, senior vice president of business development and chief
marketing officer at eRT. "eRT's ability to expand capacity and throughput on a
worldwide basis to perform the services associated with these demanding
initiatives has proven critical in enhancing our value proposition to the global
drug development community."
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues dueto variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. As a result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors that could
affect the company's financial results can be found in the company's Reports on
Forms 10-K and 10-Q filed with the Securities and Exchange Commission.
DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci of eResearchTechnology, +1-908-203-6473, or Matt
Hayden of Hayden Communications, +1-760-487-1137
Web site: http://www.ert.com/